Kerckhoff-Klinik GmbH — Clinical Trial Site

24 Registered trials

10 Currently recruiting

Organisation

Kerckhoff-Klinik GmbH

Location

Bad Nauheim, Germany

Identifier

ORG-100044532

Address

Benekestrasse 2-8, 61231, Germany

Departments

"Abteilung für Rheumatologie und Klinische Immunologie"
#40073; Rheumatologie
Abt. Administration Forschung und Lehre
Abteilung Administration und Lehre
Abteilung Administration, Forschung und Lehre
Abteilung fuer Rheumatologie, Klinische lmmunologie, Osteologie und Physikalische Medizin
Admin. Forschung und Lehre
Cardiology
Department of Cardiac Surgery
Department of Cardiology
Division of Cardiology
Herzzentrum
Herzzentrum / Abt. für Herzchirurgie und Chirurgische Intensivmedizin
Herzzentrum Abt. für Kardiologie
Justus-Liebig-Universität Gießen Campus Kerckhoff
Kardiologie
Kerckhoff-Klinik
Klinik für Kardiologie und Pneumlogie
NA

Clinical trials at this site (24)

Search interface

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 Pending

2025-522475-28-00 Pulmonary Hypertension (PH) with Heart Failure with pre 5
First-line catheter ablation for early treatment of Persistent (ongoing unless cardioverted) Atrial Fibrillation (AF) – a randomized study … Recruiting

2023-505962-28-00 Persistent symptomatic atrial fibrillation 5 2024-05-08
Effects of continued administration of empagliflozin in patients with heart failure on active SGLT2 inhibitor treatment admitted for acute d… Recruiting

2024-517977-26-00 acute decompensated heart failure 5 2025-11-25
Impact of beta blocker administration on aortic valve replacement Recruiting

2024-518731-11-00 Aortic stenosis 6 2025-08-04
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction Recruiting

2024-519219-32-00 Heart Failure With Reduced Ejection Fraction 5 2025-06-23
BIOmarker driven intensification of cardiovascular RISK factor management in patients with high risk for recurrent cardiovascular EVENTs The… Recruiting

2024-511950-35-00 Acute Myocardial Infarction 5 2025-06-12
A phase II, multicenter, 1:1 randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy of bolus applicatio… Recruiting

2024-511037-35-00 Cyclosporine A is a well known medication and is used t 4 2025-01-31
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared … Recruiting

2023-504022-19-01 Polymyositis or dermatomyositis according to 2017 EULAR 5 2024-12-13
Preventing formation of blood clots due to atrial fibrillation, a cardiac arrhythmia that first occurred after coronary bypass surgery, with… Recruiting

2024-515924-35-00 New-Onset Post-Operative Atrial Fibrillation after CABG 6 2023-01-16
A study of MK-7240/PRA023 in patients with Systemic Sclerosis Associated with Interstitial Lung Disease Recruiting

2023-509743-27-00 Systemic sclerosis associated with interstitial lung di 4 2022-04-29
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten (CK-3773274) in Adults With Hypertrophic Cardiomyo… Recruiting

2023-508963-58-00 Symptomatic hypertrophic cardiomyopathy (HCM) 4 2022-01-31
A clinical study of sotatercept in people with pulmonary hypertension (MK-7962-023) Ended

2024-515773-99-00 Pulmonary Hypertension 4 2025-05-26
A study to learn how well bimekizumab works and how safe it is in adults with psoriatic arthritis Ended

2024-511738-11-00 Psoriatic arthritis 5 2024-12-18
A study to evaluate the safety and effectiveness of a new gene therapy (XC001) for people with coronary artery disease and reduced heart fun… Ended

2025-521325-33-00 Chronic angina and left ventricular dysfunction due to 4 2026-03-18
A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended

2022-501418-69-00 Acute Coronary Syndrome 5 2023-11-21
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Cardiomyopathy Ended

2023-506352-24-00 Non-obstructive Hypertrophic Cardiomyopathy 5 2023-04-13
A multicenter, randomized, double-blind, placebo-controlled TRial evaluating Immunosuppressive treatment in patients with chronic virus-Nega… Ended

2024-512451-20-00 Patients with biopsy-proven virus-negative inflammatory 10 2023-02-28
Efficacy and Safety of secukinumab in patients with new onset of giant cell arteritis who are in clinical remission Ended

2024-512856-40-00 Giant Cell Arteritis 5 2022-09-21
A Phase 2 Study of Sotatercept for Combined Postcapillary and Precapillary Pulmonary Hypertension Treatment Ended

2023-509141-12-00 Combined Postcapillary and Precapillary Pulmonary Hyper 4 2022-04-28
Effect of antifibrotic therapy on regression of myocardial fibrosis after transcatheter aortic valve implantation (TAVI) in aortic stenosis … Ended

2024-510869-42-00 aortic stenosis patients with high fibrotic burden 4 2022-02-28
Escalated single Platelet Inhibition for one month plus Direct oral anticoagulation in patients with Atrial fibrillation and acUte coRonary … Ended

2024-512727-36-00 Patients with atrial fibrillation and ST-segment elevat 6 2021-12-21
A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICKHCM (MY… Ended

2022-502858-14-00 Hypertrophic cardiomyopathy 5 2019-09-05
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended

2023-503673-38-00 Adults at high risk of cardiovascular events without pr 5 2019-05-24
The Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial Ended

2024-518736-37-00 Risk of stroke by Atrial Fibrillation 6 2018-01-12